Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent

Journal of Psychiatric Practice

Volumn 21, Issue 2, 2015, Pages 140-149

  Preskorn, Sheldon ^a   Macaluso, Matthew ^a   Mehra, Vishaal ^b   Zammit, Gary ^c   Moskal, Joseph R ^d   Burch, Ronald M ^e  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b Artemis Institute for Clinical Research   (United States)

^c CliniLabs   (United States)

^d Northwestern University   (United States)

^e Naurex Inc   (United States)

Author keywords

Antidepressant; depression; glycine site; major depressive disorder; N methyl D aspartate (NMDA) receptor; rapid acting

Indexed keywords

ANTIDEPRESSANT AGENT; BIOGENIC AMINE; KETAMINE; PLACEBO; RAPASTINEL; TRAXOPRODIL; AMINO ACID RECEPTOR STIMULATING AGENT; GLYCINE; GLYX-13 PEPTIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOPEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HAMILTON DEPRESSION RATING SCALE 17; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VITAL SIGN; YOUNG ADULT; AGONISTS; DEPRESSIVE DISORDER, MAJOR; DRUG DEVELOPMENT; METABOLISM; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG DISCOVERY; EXCITATORY AMINO ACID AGONISTS; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929617020     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000462606.17725.93     Document Type: Article

References (25)

1. Preskorn SH. The role of proof of concept (POC) studies in drug development using the EVP-6124 POC study as an example. J Psychiatr Pract. 2014;20:59-60.
2. Warden D, Rush AJ, Trivedi MH, et al. STAR∗D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449-59.
3. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-354.
4. Zarate CA, Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63: 856-864.
5. Aan het Rot M, Collins KA, Murrough J W, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67: 139-145.
6. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspar-tate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. J Clin Psycho-phar macol. 2008;28:631-637.
7. Ibrahim L, Diaz Granados N, Jolkovsky L et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32:551-557.
8. Zarate CA, Jr., Mathews D, Ibrahim L, et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry. 2013;74:257-264.
9. Moskal JR, Burch R, Burgdorf JS, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 2014;23: 243-254.
10. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: New York State Psychiatric Institute, Biometrics Research; 2001.
11. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Therapeutics. 2010;16:322-325.
12. Burgdorf J, Zhang XL, Nicholson KL, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013;38:729-742.
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
14. Ruhé HG1, Dekker JJ, Peen J, et al. Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Compr Psychiatry. 2005;46:417-427.
15. Guy W. ECDEU Assessment Manual for Psychopharma-cology. Rockville, MD: U.S. Department of Health, Education, and Welfare; 1984.
16. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168: 1266-1277.
17. Hanan EA, Godin CS, Bruening-Wright A, et al. In vitro and in vivo safety pharmacology of assessment of GLYX-13. American College of Toxicology 33rd Annual Meeting 2012; P710.
18. Sheinin A, Shavit S, Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloser-ine. Neuropharmacology. 2001;41:151-158.
19. Dravid SM, Burger PB, Prakash A, et al. Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci. 2010;30:2741-2754.
20. Nong Y, Huang YQ, Ju W, et al. Glycine binding primes NMDA receptor internalization. Nature. 2003;422: 302-307.
21. Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affective Disorders. 2006;93: 239-243.
22. Heresco-Levy U, Gelfin G, Bloch B, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacology. 2013;16:501-506.
23. Zarate CA, Jr., Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163:153-155.
24. Skolnick P, Popik P, Trullas R. Glutamate-based antide-pressants: 20 years on. Trends Pharmacol Sci. 2009;30: 563-569.
25. de Craen AJM, Tijssen JG, de Gans J, et al. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol. 2000;247:183-188.